A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors
Latest Information Update: 11 Jun 2025
At a glance
- Drugs BGB 30813 (Primary) ; Tislelizumab (Primary)
- Indications Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BeOne Medicines
Most Recent Events
- 22 May 2025 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2024 The protocol has been amended to change in study time frame for its primary endpoint.
- 17 Dec 2024 Planned End Date changed from 1 May 2026 to 1 Dec 2026.